Tekla Capital Management’s AstraZeneca AZN Stock Holding History

Tekla Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$69.9M	Sell	488,338 -7,994	-2%	-$1.18M	2.74%	11
2023 Q1	$68.9M	Sell	496,332 -14,796	-3%	-$1.99M	2.62%	11
2022 Q4	$69.3M	Sell	511,128 -125,469	-20%	-$15.7M	2.62%	11
2022 Q3	$69.8M	Buy	636,597 +74,226	+13%	+$9.42M	2.86%	10
2022 Q2	$74.3M	Buy	562,371 +67,033	+14%	+$8.8M	2.92%	8
2022 Q1	$65.7M	Buy	495,338 +101,595	+26%	+$12.2M	2.31%	11
2021 Q4	$45.9M	Sell	393,743 -12,721	-3%	-$1.5M	1.48%	23
2021 Q3	$48.8M	Buy	406,464 +182,315	+81%	+$21.2M	1.57%	18
2021 Q2	$26.9M	Buy	224,149 +51,982	+30%	+$5.7M	0.87%	27
2021 Q1	$17.1M	Hold	172,167	–	–	0.59%	44
2020 Q4	$17.2M	Hold	172,167	–	–	0.6%	48
2020 Q3	$18.9M	Buy	172,167 +54,768	+47%	+$6.09M	0.71%	37
2020 Q2	$12.4M	Sell	117,399 -20,650	-15%	-$2.13M	0.47%	45
2020 Q1	$12.3M	Hold	138,049	–	–	0.56%	40
2019 Q4	$13.8M	Hold	138,049	–	–	0.52%	41
2019 Q3	$12.3M	Sell	138,049 -29,450	-18%	-$2.55M	0.54%	46
2019 Q2	$13.8M	Sell	167,499 -13,000	-7%	-$1.02M	0.56%	42
2019 Q1	$14.6M	Sell	180,499 -33,513	-16%	-$2.64M	0.59%	39
2018 Q4	$16.3M	Sell	214,012 -145,300	-40%	-$11.3M	0.7%	34
2018 Q3	$28.4M	Sell	359,312 -30,132	-8%	-$2.28M	1.03%	24
2018 Q2	$27.3M	Buy	389,444 +168,144	+76%	+$12.1M	1.04%	25
2018 Q1	$15.5M	Hold	221,300	–	–	0.6%	39
2017 Q4	$15.4M	Hold	221,300	–	–	0.59%	37
2017 Q3	$15M	Sell	221,300 -54,000	-20%	-$3.41M	0.54%	37
2017 Q2	$18.8M	Buy	275,300 +43,400	+19%	+$2.83M	0.7%	32
2017 Q1	$14.4M	Hold	231,900	–	–	0.56%	39
2016 Q4	$12.7M	Hold	231,900	–	–	0.54%	42
2016 Q3	$15.2M	Sell	231,900 -55,100	-19%	-$3.6M	0.59%	40
2016 Q2	$17.3M	Buy	287,000 +109,100	+61%	+$6.34M	0.71%	34
2016 Q1	$10M	Buy	+177,900	New	+$10.7M	0.43%	59

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tekla Capital Management's AZN Position: Q2 2023 in Review

Tekla Capital Management reduced its AstraZeneca (AZN) stake by 1.6% in Q2 2023, selling an estimated $1.18M and leaving 488,338 shares worth $69.9M. The position accounts for 2.74% of the portfolio, ranked #11.

Tekla Capital Management first reported a position in AZN in Q1 2016 and has held it in 30 quarters since. The position peaked at $74.3M in Q2 2022. 1,092 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Tekla Capital Management held 488,338 shares of AstraZeneca worth $69.9M as of Q2 2023.
Tekla Capital Management sold 7,994 AstraZeneca shares in Q2 2023, an estimated $1.18M.
AstraZeneca made up 2.74% of Tekla Capital Management's portfolio in Q2 2023, its #11 holding.
Tekla Capital Management first reported a position in AstraZeneca in Q1 2016 and has held it in 30 quarters since.
Tekla Capital Management's AstraZeneca position peaked at $74.3M in Q2 2022.
1,092 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.